BlackRock Fund Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-6,014,689
| Closed | -$2.11M | – | 4323 |
|
|
2016
Q3 | $2.11M | Buy |
6,014,689
+1,248,248
| +26% | +$437K | ﹤0.01% | 3148 |
|
|
2016
Q2 | $2.22M | Buy |
4,766,441
+42,824
| +0.9% | +$20K | ﹤0.01% | 3164 |
|
|
2016
Q1 | $6.42M | Buy |
4,723,617
+366,359
| +8% | +$498K | ﹤0.01% | 2609 |
|
|
2015
Q4 | $6.41M | Buy |
4,357,258
+119,534
| +3% | +$176K | ﹤0.01% | 2696 |
|
|
2015
Q3 | $6.7M | Sell |
4,237,724
-52,612
| -1% | -$83.1K | ﹤0.01% | 2617 |
|
|
2015
Q2 | $7.29M | Buy |
4,290,336
+210,225
| +5% | +$357K | ﹤0.01% | 2688 |
|
|
2015
Q1 | $5.67M | Buy |
4,080,111
+812,862
| +25% | +$1.13M | ﹤0.01% | 2778 |
|
|
2014
Q4 | $4.93M | Buy |
3,267,249
+435,718
| +15% | +$658K | ﹤0.01% | 2884 |
|
|
2014
Q3 | $5.83M | Sell |
2,831,531
-117,303
| -4% | -$242K | ﹤0.01% | 2659 |
|
|
2014
Q2 | $9.02M | Sell |
2,948,834
-306,484
| -9% | -$938K | ﹤0.01% | 2482 |
|
|
2014
Q1 | $8.14M | Buy |
3,255,318
+486,520
| +18% | +$1.22M | ﹤0.01% | 2517 |
|
|
2013
Q4 | $13.7M | Sell |
2,768,798
-68,311
| -2% | -$339K | ﹤0.01% | 2197 |
|
|
2013
Q3 | $6.47M | Buy |
2,837,109
+747,821
| +36% | +$1.71M | ﹤0.01% | 2619 |
|
|
2013
Q2 | $4.64M | Buy |
+2,089,288
| New | +$4.64M | ﹤0.01% | 2733 |
|
BlackRock Fund Advisors's RXII Position: Q4 2016 in Review
BlackRock Fund Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 6,014,689 shares — an estimated $2.11M sold.
BlackRock Fund Advisors first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $13.7M in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- BlackRock Fund Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- BlackRock Fund Advisors sold 6,014,689 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $2.11M.
- BlackRock Fund Advisors first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- BlackRock Fund Advisors's GALENA BIOPHARMA INC COM position peaked at $13.7M in Q4 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.